A phase i study of bortezomib in combination with standard 5-fluorouracil and external-beam radiation therapy for the treatment of locally advanced or metastatic rectal cancer

Clinical Colorectal Cancer

Volumn 9, Issue 2, 2010, Pages 119-125

  O'Neil, Bert ^a   Raftery, Laura ^a   Calvo, Benjamin ^a   Chakravarthy, A Bapsi ^c   Ivanova, Anastasia ^b   Myers, Michael ^a   Kim, Hong Jin ^a   Chan, Emily ^c   Wise, Paul ^c   Caskey, Laura ^a   Bernard, Stephen ^a   Sanoff, Hanna ^a   Goldberg, Richard ^a   Tepper, Joel ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b IL   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Maximum tolerated dose; NF B; Proteasome inhibitors; PS 341

Indexed keywords

BORTEZOMIB; FLUOROURACIL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 1;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; ENDOSCOPIC ECHOGRAPHY; EXTERNAL BEAM RADIOTHERAPY; FEMALE; GASTROESOPHAGEAL REFLUX; GENE EXPRESSION; GENE TARGETING; HAND FOOT SYNDROME; HUMAN; HYPERGLYCEMIA; HYPOALBUMINEMIA; HYPOKALEMIA; ILEUS; LYMPHOCYTOPENIA; MALE; MAXIMUM TOLERATED DOSE; METASTASIS; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; RADIATION DOSE; RECTUM BIOPSY; RECTUM CARCINOMA; STOMATITIS; THORAX PAIN; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR BIOPSY;

EID: 77950841318     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2010.n.017     Document Type: Article

References (16)

1. Gerard JP, Conroy T, Bonnetain F, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 2006; 24:4620-4625 (Pubitemid 46630960)
2. Bosset JF, Calais G, Mineur L, et al. Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results-EORTC 22921. J Clin Oncol 2005; 23:5620-5627 (Pubitemid 46300157)
3. Ngan SY, Burmeister BH, Fisher R, et al. Early toxicity from preoperative radiotherapy with continuous infusion 5-fluorouracil for resectable adenocarcinoma of the rectum: a Phase II trial for the Trans-Tasman Radiation Oncology Group. Int J Radiat Oncol Biol Phys 2001; 50:883-887 (Pubitemid 32594830)
4. Voorhees PM, Dees EC, O'Neil B, et al. The proteasome as a target for cancer therapy. Clin Cancer Res 2003; 9:6316-6325 (Pubitemid 38031815)
5. Russo SM, Tepper JE, Baldwin AS, Jr, et al. Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB. Int J Radiat Oncol Biol Phys 2001; 50:183-193
6. Millennium Pharmaceuticals. VELCADE (bortezomib) for Injection: Prescribing Information. Cambridge, MA: Millennium Pharmaceuticals, Inc; 2003.
7. Li Z, Xia L, Lee LM, et al. Effector genes altered in MCF-7 human breast cancer cells after exposure to fractionated ionizing radiation. Radiat Res 2001; 155:543-553 (Pubitemid 32260252)
8. Izzo JG, Wu X, Wu TT, et al. Therapy-induced expression of NF-kappaB portends poor prognosis in patients with localized esophageal cancer undergoing preoperative chemoradiation. Dis Esophagus 2009; 22:127-132
9. Scartozzi M, Bearzi I, Pierantoni C, et al. Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy. J Clin Oncol 2007; 25:3930-3935 (Pubitemid 47477270)
10. Iqbal S, Cole S, Yang D, et al. Phase I study of PS-341 (bortezomib) with 5-fluorouracil/ leucovorin (5-FU/LV) in advanced solid tumors: A California Cancer Consortium study. J Clin Oncol 2004; 22(14 suppl): (abstract 2057).
11. Van Waes C, Chang AA, Lebowitz PF, et al. Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2005; 63:1400-1412
12. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351:1731-1740
13. Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999; 59:2615-2622 (Pubitemid 29269108)
14. Rajkumar SV, Richardson PG, Hideshima T, et al. Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 2005; 23:630-639 (Pubitemid 46224241)
15. Jagannath S, Barlogie B, Berenson JR, et al. Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma. Br J Haematol 2008; 143:537-540
16. Allen C, Saigal K, Nottingham L, et al. Bortezomib-induced apoptosis with limited clinical response is accompanied by inhibition of canonical but not alternative nuclear factor-{kappa}B subunits in head and neck cancer. Clin Cancer Res 2008; 14:4175-4185